The combination of the MIBG myocardial scintigraphy and DATSPECT contributes to the diagnosis of PD and other related disorders.
Objective: To evaluate MIBG and DAT SPECT for the diagnosis of Parkinson’s disease (PD) and related disorders, we performed 123I-meta-iodobenzylguanzylguanidine (MIBG) myocardial scintigraphy and (123I)-FP-CIT…SPECT imaging of striatal DAT availability in Parkinson’s: changes over time and relevance to dyskinesias
Objective: This study was designed to explore in Parkinson’s disease (PD) the role of dopamine transporter (DAT)-specific single photon emission computed tomography (SPECT) imaging as a…A neuroimaging-based model for disease progression in Parkinson’s disease
Objective: We model the rate of disease progression over 4 years in subjects with Parkinson’s disease based on neuroimaging features acquired at baseline. Background: DaTSCAN…Profound reduction of DAT-SPECT signal in multiple system atrophy (MSA)
Objective: To evaluate the extent of degeneration in dopamine nerve terminal in striatum in the patients with MSA-P and MSA-C, and to compare the progression…Utility of DaTscan Imaging in Differentiating Drug Induced Parkinsonism from IPD and Other Forms of Parkinsonism
Objective: To determine clinical correlates which differentiate drug induced Parkinsonism (DIP) from IPD and other forms of Parkinsonism using DaT-SPECT imaging. Background: DaT-SPECT imaging is…Semiquantitative analyses of DAT-SPECT imaging with an automated striatal analysis software in differential diagnosis of neurodegenerative parkinsonism
Objective: We investigate the usefulness Dopamine transporter (DAT)-SPECT with an automated striatal analysis software in differential diagnosis of neurodegenerative parkinsonism. Background: DAT-SPECT imaging is sensitive…Global Regulatory Agencies Support the Use of Dopamine Transporter Neuroimaging for Subject Selection in Clinical Trials Targeting Early Stage Parkinson’s Disease – on behalf of Critical Path for Parkinson’s (CPP) Consortium
Objective: A key goal of the Critical Path for Parkinson’s Consortium (CPP) is to qualify, with regulatory agencies, drug development tools for use in PD…Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Objective: To assess the neurobiological substrate of initial cognitive decline in Parkinson’s disease (PD) to inform patient management, clinical trial design, and development of treatments.…Non-motor symptoms in Parkinson’s disease and putamen dopamine transporter uptake (DaTscan) uptake: a survey of 85 patients
Objective: We addressed association between 30 non-motor symptoms (NMS) (using the validated Parkinson’s disease (PD) NMS Scale (NMSS)), and DaTscan putamen uptake ratios as part…Assessment of cognitive impairment using FP-CIT SPECT
Objective: We aimed to assess the cognitive impairment using FP-CIT SPECT in mild cognitive impairment or dementia patients. Background: In general, FP-CIT SPECT reflect pre-synaptic dopamine…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- Next Page »